

303 Rec'd PCT/PTC 22 DEC 1998

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EL 073188355US

Express Mail Label Number

December 22, 1998

Date of Deposit

Form PTO-1390-MOD (REV 10-96)		U. S. Department of Commerce Patent and Trademark Office	ATTORNEY'S DOCKET NUMBER 4-20921/A/PCT
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 09/202805
INTERNATIONAL APPLICATION NO. PCT/EP97/03172	INTERNATIONAL FILING DATE 18 June 1997 (18.06.97)	PRIORITY DATE CLAIMED 27 June 1996 (27.06.96)	
TITLE OF INVENTION SOLID ORAL DOSAGE FORMS OF VALSERTAN			
APPLICANT(S) FOR DO/EO/US WAGNER ET AL.			

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau. (See Form PCT/IB/308)
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☐ An executed Declaration and Power of Attorney (original or copy) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included.

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A FIRST preliminary amendment.
☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information: (Unsigned Declaration)

17. ☒ The following fees are submitted:**BASIC NATIONAL FEE (37 CFR 1.492(a) (1)-(5)):**

Search Report has been prepared by the EPO or JPO \$840

International preliminary examination fee paid to USPTO (37 CFR 1.482)
..... \$670

No international preliminary examination fee paid to USPTO (37 CFR 1.482)
but international search fee paid to USPTO (37 CFR 1.445(a)(2)). \$760

Neither international preliminary examination fee (37 CFR 1.482) nor
international search fee (37 CFR 1.445(a)(2)) paid to USPTO. \$970

International preliminary examination fee paid to USPTO (37 CFR 1.482)
and all claims satisfied provisions of PCT Article 33(2)-(4). \$96

CALCULATIONS PTO USE ONLY**ENTER APPROPRIATE BASIC FEE AMOUNT =**

\$ 840

Surcharge of \$130 for furnishing the oath of declaration later than ☐ 20 ☐ 30
months from the earliest claimed priority date (37 CFR 1.492(e)).

\$

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	26	- 20 = 6	X \$ 18
Independent claims	2	- 3 = 0	X \$ 78
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$ 260
TOTAL OF ABOVE CALCULATIONS =			\$ 948

Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).			\$
SUBTOTAL =			\$ 948

Processing fee of \$130 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).			+	\$
TOTAL NATIONAL FEE =			\$ 948	

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property			+	\$
TOTAL FEES ENCLOSED =			\$ 948	

Amount to be:			\$
refunded			
charged			\$

Amount to be:			\$
refunded			
charged			\$

Amount to be:			\$
refunded			
charged			\$

Amount to be:			\$
refunded			
charged			\$

Amount to be:			\$
refunded			
charged			\$

Amount to be:			\$
refunded			
charged			\$

Amount to be:			\$
refunded			
charged			\$

Amount to be:			\$
refunded			
charged			\$

Amount to be:			\$
refunded			
charged			\$

Amount to be:			\$
refunded			
charged			\$

Amount to be:			\$
refunded			
charged			\$


Amount to be:			\$
refunded			
charged			\$

Amount to be:			\$
refunded			
charged			\$

Amount to be:			\$
refunded			
charged			\$

a. ☐ A check in the amount of \$_____ to cover the above fees is enclosed.b. ☒ Please charge Deposit Account No. 19-0134 in the amount of \$948 to cover the above fees. A duplicate copy of this form is enclosed.c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134.**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.**Send all correspondence to the address associated with
Customer No. 001095, which is currently:

Michael W. Glynn
Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027


Stephen G. Kalinchak
Attorney for Applicants
Reg. No. 38,747
(908) 522-6763

09/202805

CASE 4-20921/A/PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

300 Rec'd PCT/PTO 22 DEC 1998

IN RE PCT NATIONAL STAGE APPLICATION OF

WAGNER ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP97/03172

FILED: 18 JUNE 1997

U.S. APPLICATION NO: Not Yet Known

35 USC §371 DATE: Herewith

FOR: SOLID ORAL DOSAGE FORMS OF VALSERTAN

Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Prior to calculation of the national filing fees, please amend the application as follows:

IN THE CLAIMS

Please cancel claims 26 and 27.

Please amend the following claims:

Claim 3, line 1, delete "or claim 2".

Claim 4, line 1, delete "any of the preceding claims" and substitute therefor -- claim 1 --.

Claim 5, line 1, delete "any of the preceding claims" and substitute therefor -- claim 1 --.

Claim 6, line 1, delete "any of the preceding claims" and substitute therefor -- claim 1 --.

Claim 7, line 1, delete "any of the claims 1 to 3" and substitute therefor -- claim 1 --.

Claim 9, line 1, delete "claims 7 or 8" and substitute therefor -- claim 8 --.

Claim 10, line 1, delete "any of the claims 7 to 9" and substitute therefor -- claim 8 --.

Claim 11, line 1, delete "any of the claims 7 to 9" and substitute therefor -- claim 8 --.

Claim 12, line 1, delete "any of the preceding claims" and substitute therefor -- claim 8 --.

Claim 13, line 1, delete "any of the preceding claims" and substitute therefor -- claim 8 --.

Claim 16, line 1, delete "any of the preceding claims" and substitute therefor -- claim 8 --.

Claim 17, line 1, delete "any of the preceding claims" and substitute therefor -- claim 8 --.

Claim 18, lines 1-2, delete "any of the preceding claims" and substitute therefor -- claim 8 --.

564050 "50820260

Claim 20, line 1, delete "or 19".

Claim 21, line 1, delete "any of the claims 18 to 20" and substitute therefor -- claim 18 --.

Claim 22, line 1, delete "any of the claims 18 to 21" and substitute therefor -- claim 18 --.

Claim 25, lines 1-2, delete "any of the claims 18 to 22" and substitute therefor --18--.

Please add the following new claim:


--28. A method of treating hypertension, congestive heart failure, angina, myocardial infarction, arteriosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, left ventricular hypertrophy, cognitive dysfunction, headache, or chronic heart failure, wherein the method comprises administering a solid oral dosage form as defined in claim 1 to a host in need of such treatment.--

REMARKS

The claims have been amended to eliminate multiple dependencies and to place the claims in a form more consistent with United States patent practice. Early examination of the claims and allowance of the same are respectfully requested.

Respectfully submitted,

Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6763



Stephen G. Kalinchak
Attorney for Applicants
Reg. No. 38,747

Date: *December 22, 1998*

SOLID ORAL DOSAGE FORMS OF VALSARTAN

The invention relates to solid oral dosage forms containing valsartan, in particular solid oral dosage forms containing valsartan and hydrochlorothiazide (HCTZ) and a process of forming the same.

The angiotensin II receptor antagonist - Valsartan - is known to be effective in the treatment of congestive heart failure and reducing blood pressure irrespective of age, sex or race and is also well tolerated. Its combination with HCTZ is also known for the treatment of hypertension.

The oral administration of such pharmaceutical agents as tablets or capsules has certain advantages over parenteral administration such as i.v. or i.m.: Diseases requiring treatment with painful injectable formulations are considered to be more serious than those conditions which can be treated with oral dosage forms. However, the major advantage with oral formulations is held to be their suitability for self administration whereas parenteral formulations have to be administered in most cases by a physician or paramedical personnel.

However, valsartan is difficult to formulate and heretofore it has not been possible to make oral formulations in the form of tablets in a reliable and robust way.

Capsules are undesirable since large capsules must be used to accommodate effective amounts of active agent, which in the case of valsartan, is of low density and is therefore rather bulky.

We have now found a solid oral dosage form containing valsartan or a pharmaceutically acceptable salt thereof optionally in combination with HCTZ which can be produced according to a reliable and robust process, which solid oral dosage form is small relative to the amount of active agent used. Said solid oral dosage forms are smaller, for a given amount of active agent, than any known formulations of this active substance.

09203305.050799
664050.5020250

According to the invention there is provided a solid oral dosage form comprising

- a) an active agent containing an effective amount of valsartan or a pharmaceutically acceptable salt thereof and
- b) pharmaceutically acceptable additives suitable for the preparation of solid oral dosage forms by compression methods

preferably wherein the active agent is present in an amount of more than 35 % by weight, preferably more than 50 % by weight based on the total weight of the solid oral dosage form. In particular, the amount of active agent may be present in an amount of from 45 to 65 % by weight, e.g. 57 to 62 % by weight.

Solid oral dosage forms according to the invention provide for the administration of the active substance in a smaller oral form than was heretofore possible for a given unit dose of active agent. Furthermore, the oral dosage forms obtained are stable both to the production process and during storage, e.g. for 2 years in conventional packaging, e.g. sealed aluminium blister packs.

By "effective amount" is meant the amount of active agent which halts or reduces the progress of the condition being treated or which otherwise completely or partly cures or acts palliatively on the condition. Such an amount can be easily determined by a person skilled in the art by routine experimentation and with no undue burden.

In a solid oral dosage form according to the invention wherein the active agent consists entirely of valsartan or a pharmaceutically acceptable salt thereof, it is preferred if the active agent is present in an amount of from 10 to 250 mg, more preferable 40 to 160 mg, most preferably 40 to 80 mg, e.g. 40, 80 or 160 mg.

09202805.050799

The active agent valsartan is particularly suitable for combination with other active agents, e.g. HCTZ.

Accordingly, in a further embodiment of the invention there is provided a solid oral dosage form as hereinabove described additionally containing HCTZ as a component of the active agent.

It has been found that valsartan, or a pharmaceutically acceptable salt thereof, combined in a dose range from about 10 to 250 mg with hydrochlorothiazide in a dose range from about 6 to 60 mg, is suitable for more efficient treatment of hypertension. With these dose ranges of the combined active agents, valsartan is found to have a greater efficacy in reducing elevated blood pressure to normal levels than it would have if used at the same dose range in monotherapy. Moreover, when hydrochlorothiazide is being administered in combination with valsartan, the diuretic agent is more effective as compared to monotherapy at the dose range indicated. Particularly suitable is a dose range from about 50 and 100 mg valsartan or a pharmaceutically acceptable salt thereof and from about 10 to 30 mg hydrochlorothiazide. More preferred is a unit dose of about 80 mg valsartan and 12.5 mg or 25 mg of hydrochlorothiazide and 160 mg valsartan and 12.5 mg or 25 mg of hydrochlorothiazide. The weight ratio of valsartan or a pharmaceutically acceptable salt thereof to hydrochlorothiazide is from about 1:6 to about 42:1, more preferably 2:1 to 13:1, most preferably 2:1 to 10:1.

The present invention particularly relates to a solid oral dosage form, which contain as the active agent a)

a unit dose between about 10 and 250 mg, especially between about 50 and 100 mg, of valsartan or a pharmaceutically acceptable salt thereof; and

a unit dose between about 6 and 60 mg, especially between about 10 and 30 mg, of hydrochlorothiazide.

09202805.050799

An especially preferred embodiment of the invention is a solid oral dosage form, which contain as the active agent a)

a unit dose of about 80 mg or 160 mg of valsartan or a pharmaceutically acceptable salt thereof; and

a unit dose of about 12.5 mg hydrochlorothiazide.

The preparation of valsartan is described in the U.S. patent specification no. 5 399 578 which is incorporated herein by reference. A pharmaceutically acceptable salt of valsartan can be prepared in a manner known per se. Thus for example, acid addition salts are obtained by treatment with an acid or a suitable ion exchange agent. Such salts can be converted to free acid in a conventional manner by treatment with a suitable basic agent.

Valsartan is preferably in its free form, that is, not in one of its salt forms.

Hydrochlorothiazide is a known therapeutic agent which is useful in the treatment of hypertension.

A solid oral dosage form according to the invention comprises additives conventional in the dosage form in question. Tableting aids, commonly used in tablet formulation can be used and reference is made to the extensive literature on the subject, see in particular Fiedler's "Lexicon der Hilfstoffe", 4th Edition, ECV Aulendorf 1996 which is incorporated herein by reference. These include but are not limited to disintegrants, binders, lubricants, glidants, stabilising agents, fillers or diluents, surfactants and the like.

As disintegrants one can particularly mention CMC-Ca, CMC-Na, crosslinked PVP (Crospovidone, Polyplasdone of Kollidon XL), Alginic acid, sodium alginate and guar gum, most preferably crosslinked PVP, Crospovidone, crosslinked CMC and Ac-Di-Sol.

09202805 050799

As binders one can particularly mention starches, e.g. potato starch, wheat starch, corn starch, microcrystalline cellulose, e.g. products known under the registered trade marks Avicel, Filtrak, Heweten or Pharmacel, hydroxypropyl cellulose, hydroxyethyl cellulose and hydroxypropylmethyl cellulose, e.g. hydroxypropyl cellulose having a hydroxypropyl content of 5 to 16 % by weight and a Mw of from 80 000 to 1 150 000, more particularly 140 000 to 850 000.

As glidants one can mention in particular colloidal silica, e.g. Aerosil, magnesium trisilicate, powdered cellulose, starch, talc and tribasic calcium phosphate.

As fillers or diluents one can mention confectioner's sugar, compressible sugar, dextrates, dextrin, dextrose, lactose, mannitol, microcellulose, in particular having a density of about 0.45g/cm^3 , e.g. Avicel, powdered cellulose, sorbitol, sucrose and talc.

As lubricants one can mention in particular Mg, Al or Ca stearate, PEG 4000 - 8000 and talc.

One or more of these additives can be selected and used by the skilled artisan having regard to the particular desired properties of the solid oral dosage form by routine experimentation and without any undue burden.

The amount of each type of additive employed, e.g. glidant, binder, disintegrant, filler or diluent and lubricant may vary within ranges conventional in the art. Thus for example, the amount of glidant may vary within a range of from 0.1 to 10% by weight, in particular 0.1 to 5% by weight, e.g. 0.1 to 0.5% by weight; the amount of binder may vary within a range of from about 10 to 45% by weight, e.g. 20 to 30% by weight; the amount of disintegrant may vary within a range of from 2 to 20% by weight, e.g. 15% by weight; the amount of filler or diluent may vary within a range of from 15 to 40% by weight; whereas the amount of lubricant may vary within a range of from 0.1 to 5.0% by weight.

It is a characteristic of the present solid oral dosage forms that they contain only a relatively small amount of additives given the high content of active agent. This enables the production of physically small unit dosage forms. The total amount of additives in a given unit dosage may be about 65 % or less by weight based on the total weight of the solid oral dosage form, more particularly about 50 % or less. Preferably the additive content is in the range of about 35 to 55 % by weight, more particularly 45 to 55 % by weight, e.g. 38 to 43 % by weight.

The absolute amounts of each additive and the amounts relative to other additives is similarly dependent on the desired properties of the solid oral dosage form and may also be chosen by the skilled artisan by routine experimentation without undue burden. For example, the solid oral dosage form may be chosen to exhibit accelerated and/or delayed release of the active agent with or without quantitative control of the release of active agent.

Thus, where accelerated release is desired, e.g. about 90% release within a ten minute, more particularly a five minute period, a disintegrant such as crosslinked polyvinyl pyrrolidone, for example those products known under the registered trade marks Polyplasdone®XL or Kollidon®CL, in particular having a molecular weight in excess of 1 000 000, more particularly having a particle size distribution of less than 400 microns or less than 74 microns, or reactive additives (effervescent mixtures) that effect rapid disintegration of the tablet in the presence of water, for example so-called effervescent tablets that contain an acid in solid form, typically citric acid, which acts in water on a base containing chemically combined carbon dioxide, for example sodium hydrogencarbonate or sodium carbonate, and releases carbon dioxide.

Whereas if delayed release is desired one can employ pellet coating technology, wax matrix systems, polymer matrix tablets or polymer coatings conventional in the art.

09202305.050799

Quantitative control of the release of the active agent can be achieved by conventional techniques known in the art. Such dosage forms are known as oral osmotic systems (OROS), coated tablets, matrix tablets, press-coated tablets, multilayer tablets and the like.

In a solid oral dosage form wherein the active agent consist entirely of valsartan or a pharmaceutically acceptable salt thereof, preferred additives are microcrystalline cellulose, hydroxypropylcellulose, carboxymethylcellulose (CMC) or CMC-Ca, Mg, Ca or Al stearate, anhydrous colloidal silica and talc. The amounts of additive employed will depend upon how much active agent is to be used. The stearate, e.g. Mg stearate is preferably employed in amounts of 1.0 to 5.0% by weight, e.g. 1.5% to 3.0 % by weight. Whereas the silica is preferably employed in an amount of from 0.5 to 10% by weight.

In a solid oral dosage form wherein the active agent consists of a combination of both valsartan or a pharmaceutically acceptable salt thereof and HCTZ it is preferred to employ additives selected from any of those additives recited in the previous paragraph and crosslinked polyvinylpyrrolidone. The stearate is preferably employed in an amount of from 1 to 5% by weight, e.g. 3%. The cellulose material, e.g. microcrystalline cellulose is preferably present in an amount of 10 to 30%, e.g. 21%. The silica is preferably present in an amount of from 0.5 to 10%, e.g. 1% by weight. The crosslinked polyvinylpyrrolidone is preferably present in an amount of from 10 to 20%, e.g. about 13% by weight. Particularly preferred solid oral dosage forms contain as additives microcrystalline cellulose and crosslinked polyvinylpyrrolidone (PVP).

The solid oral dosage forms according to the present invention may be in the form of dragées in which case the solid oral dosage form is provided with a coating typically a sugar, shellac or other film coating entirely conventional in the art. Attention is drawn to the numerous known methods of coating employed in the art, e.g. spray coating in a fluidized bed, e.g. by the known methods using apparatus available from Aeromatic, Glatt, Wurster or Hüttlin, in a perforated pan by the Accela Cota method, or to the

09202305.050799

submerged sword coating method. The additives commonly used in confectioning are employed in such methods.

The solid oral dosage forms of the present invention are useful for lowering the blood pressure, either systolic or diastolic or both. The conditions for which the instant invention is useful include, without limitation, hypertension (whether of the malignant, essential, reno-vascular, diabetic, isolated systolic, or other secondary type), congestive heart failure, angina (whether stable or unstable), myocardial infarction, arteriosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, left ventricular hypertrophy, cognitive dysfunction (such as Alzheimer's) and stroke.

The exact dose of active agent and the particular formulation to be administered depend on a number of factors, e.g. the condition to be treated, the desired duration of the treatment and the rate of release of the active agent. For example, the amount of the active agent required and the release rate thereof may be determined on the basis of known in vitro or in vivo techniques, determining how long a particular active agent concentration in the blood plasma remains at an acceptable level for a therapeutic effect.

The invention provides in another of its aspects a process of making a solid oral dosage form as hereinabove described. Such solid oral dosage form may be produced by working up components a) and b) defined hereinabove in appropriate amounts, to form unit dosage forms.

In a preferred embodiment there is provided a process of making the solid oral dosage forms as hereinabove described comprising the steps of

- i) grinding the active agent and pharmaceutically acceptable additives,

- ii) subjecting a mixture of the ground active agent and additives to compression to form a coprimate
- iii) converting the coprimate to form a granulate and
- iv) compressing the granulate to form the solid oral dosage form.

The process is carried out in the absence of water, i.e. it is a dry compression method. The process may be carried out under ambient conditions of temperature and humidity; it is not necessary to ensure that the process is carried out in a dry atmosphere.

The initial grinding step i) may be carried out according to conventional milling methods or micronisation methods.

The active agent and the additives can be milled either individually or together to particle sizes from about 0.1 μ to about 200 μ , preferably 1.0 μ to 100 μ . At least 90 % of the crystals of both the active agent and the additives are present in these ranges. Particles of this size are obtained by conventional comminution methods, e.g. grinding in an air jet mill, hammer and screen mill, fine impact mill, ball mill or vibrator mill.

Micronisation is preferably effected by known methods using an ultrasonic disintegrator, e.g. of the BRANSON Sonifier type, or by stirring a suspension with a high speed agitator, for example with a stirrer of the HOMOREX type.

The ground particles may optionally at this stage be sieved and mixed according to known methods.

09202805.1050799
662050" 50820260

Compression to form a coprimate requires the compaction of the dry ground components. Compaction may be carried out using a slugging technique or preferably, roller compaction. Roller compaction apparatus is conventional and essentially utilises two rollers which roll towards each other. A hydraulic ram forces one of the rollers against the other to exert a compacting force against the ground particles fed into the roller compactor via a screw conveyor system.

A compaction force of between 25 and 65 kN is preferably used. Within this range of compaction forces it has surprisingly been found that for each particular formulation a minimum compaction force should be used in order to obtain a solid oral dosage form wherein the granulate disintegrates into discrete primary particles at a desirable rate, e.g. disintegration occurs approximately six times faster for a solid oral dosage form compressed above a minimum compaction force. Such a rapid disintegration rate is unusual for tablets and is similar to the disintegration rate of a capsule formulation. The particular minimum compaction force is dependent on the active agent content in any given formulation and therefore also depends on the amount and nature of the additives present.

A solid oral dosage form containing an active agent consisting of 80 mg valsartan and 12.5 mg HCTZ, and appropriate additives in appropriate quantities is preferably made by a process wherein the compaction force used to produce the coprimate is at least 30 kN. Appropriate additives in appropriate quantities for this active agent may be 31.5 mg microcrystalline cellulose, 1.5 mg anhydrous colloidal silica, 4.5 mg magnesium stearate and 20 mg crosslinked PVP.

A solid oral dosage form comprising a unit dose of 160 mg valsartan and 12.5 mg HCTZ, and appropriate additives in appropriate quantities is preferably made by a process wherein the compaction force used to produce the coprimate is at least 25 kN. Appropriate additives in appropriate quantities for this active agent may be 75.5 mg microcrystalline cellulose, 3.0 mg anhydrous colloidal silica, 9.0 mg magnesium stearate and 40 mg crosslinked PVP.

09202805 050799

Given this information, the skilled addressee would clearly be able to determine the minimum compaction force for other formulations using routine experimentation and without undue burden.

The roller speed is set at between 1 and 15 rpm and is preferably 1.3 to 7.5 rpm. After passing through the rollers the compacted mass (the coprimate) resembles a thin ribbon in segments.

The coprimate may be screened and or milled to produce the granulate. Screening in its simplest form involves the passing of the coprimate emerging from the rollers through a sieve under mechanical pressure. More preferably, the coprimate is screened using an oscillating mill, e.g. a MGI 624 Frewitt (Key International Inc.).

The granulate thus formed has a rather wide particle size distribution e.g. from 9 to 340 microns. At this stage of the roller compaction process it is conventional to sort the under-sized and over-sized particles and remove them from the granulate for recycling or recirculation. Thus removed the over- and under-sized particles are typically compacted an additional one or more times in order to obtain the desired particle size distribution of the granulate. Such a process is time consuming and therefore increases the cost of manufacture of solid oral dosage forms. Furthermore, the additional passes through the roller compactor under such high compaction forces can have deleterious effects on the active agent and also render the granulate less suitable for compression into the solid oral dosage form.

It has been found however, that the granulate first emerging from the roller compactor after screening or milling and containing both over- and under-sized particles can in fact be compressed to form solid oral dosage forms without affecting the properties of the solid oral dosage form.

09202305.050799

The compression of the granulates to tablet cores can be carried out in a conventional tableting machine, e.g. in an EK-0 Korsch eccentric tableting machine or a rotary compression machine, preferably at a compression greater than 2 kN. The tablet cores may vary in shape and be, for example, round, oval, oblong, cylindrical or any other suitable shape, and may also vary in size depending on the concentration of the therapeutic agents. A characteristic of tablets according to the invention is their small size having regard to the amount of active agent contained therein.

In a preferred embodiment of the invention tablets obtained by the compression method described above are slightly oval. The edges of the tablets may be bevelled or rounded.

In a particularly preferred embodiment of the invention a solid oral dosage form is compressed in the form of a tablet having an oblong shape in which the ratio of dimensions length:width:height is 2.5 - 5.0: 0.9 - 2.0: 1.0 and preferably in which the base and top face of the tablet independently of one another are planar or convexly curved about the longitudinal axis; the side faces are planar, the end faces can be of any shape and the edges are optionally bevelled or rounded.

In a particularly preferred embodiment of the invention a solid oral dosage form is compressed, from the granulate, in the form of a tablet of oblong shape in which the length is approximately 10.0 to 11.0 mm, the width approximately 5.0 to 6.0 mm and the height approximately 3.0 to 4.0 mm.

In another particularly preferred embodiment of the invention a solid oral dosage form is compressed from granulates in the form of a tablet of oblong shape in which the length is approximately 15.0 to 16.0 mm, the width approximately 6.0 to 7.0 mm and the height approximately 3.5 to 5.0 mm.

In yet another preferred embodiment of the invention there is provided a tablet which is essentially disc-shaped with the upper and lower faces having a slightly convex surface. Preferably the tablet has a diameter of about 8 to 8.5 mm and a depth of about

0920305.0020250

3 to 3.5 mm, or a diameter of about 16 mm and a depth of about 6 mm. The tablets may occupy a volume from about 0.1 cm^3 to about 0.45 cm^3 , more particularly 0.2 to 0.3 cm^3 , e.g. about 0.125 cm^3 or 0.25 cm^3 .

They may furthermore be transparent, colourless or coloured and also marked so as to impart to this product an individual appearance and to make them instantly recognizable. The use of dyes can serve to enhance the appearance as well as to identify the compositions. Dyes suitable for use in pharmacy typically include carotinoids, iron oxides or chlorophyll.

There now follows a series of examples which serve to illustrate the invention.

09200305 050799
55/050 5000260

Example 1

Formula

valsartan	80.0 mg(53.3 %)
hydrochlorothiazide	12.5 mg(8.3 %)
colloidal anhydrous silica AEROSIL	1.5 mg(1.0 %)
microcrystalline cellulose AVICEL	31.5 mg(21.0 %)
polyvinylpyrrolidone CROSPVIDONE	20.0 mg(13.3 %)
magnesium stearate	4.5 mg(3.0 %)
	<u>150.0 mg</u>

Method

The components except for a portion of the magnesium stearate are blended in a container mixer. The blended material is sieved and pre-blended for an additional period of time in a container mixer. The blended material is compacted using a roller compactor (Bepex Pharmapaktor L 200/50 P, Hosokawa Micron Group) by applying a compaction force of 25-65 kN and a roller speed of 1.3-7.5 rpm. The compacted material is sieved again and the remaining portion of the magnesium stearate is added and final blended in a container mixer. Then 150 mg of the homogenous mixture is compressed into tablets using ovaloid punches (10 x 5.2 mm). The tablets obtained have a length of 10.0-10.2 mm, a width of 5.2-5.4 mm and a height of 3.3-3.9 mm.

Example 1a

A solid oral dosage form prepared according to Example 1 is coated with a film coating formulation:

Cellulose H-P-M683	2.76	mg
Fe Oxide (Yellow) 17268	0.025	
Fe Oxide (Red) 17266	0.025	
PEG 8000 (flakes)	0.5	
Talc PH	2.0	
Titanium dioxide PH	0.7	
Deionised water	2.5	

Ethanol + 5% Isopropyl alcohol

20.0

Method

The PEG and cellulose are dissolved in the deionised water. The remaining components are suspended in the resulting solution. A spray coater apparatus (Dria-coater DRC-500, Powrex Ltd) is charged with the solid oral dosage form of Example 1. The coating formulation is sprayed into the solid oral dosage form rotating in the apparatus at 6-12 rpm. Spray pressure is 1.9 - 2.2 Kg/cm² and the spray rate is 5.9 - 7.9 g/min.

Thereafter the coated solid oral dosage form is dried in the coater apparatus at a temperature of 40°C until a moisture content in the coated solid oral dosage form is less than 2.5% by weight.

The tablets obtained have a length of 10.1-10.3 mm, a width of 5.3-5.5 mm and a height of 3.4-4.0 mm

Example 2

Formula

valsartan	160.0 mg(53.3 %)
hydrochlorothiazide	12.5 mg(8.3 %)
colloidal anhydrous silica AEROSIL	3.0 mg(1.0 %)
microcrystalline cellulose AVICEL	75.5 mg(21.0 %)
polyvinylpyrrolidone CROSPVIDONE	40.0 mg(13.3 %)
magnesium stearate (FAC I)	9.0 mg(3.0 %)
	<u>300.0 mg</u>

A 300.0 mg tablet is formed according to the method described in Example 1. The tablets obtained have a length of 15.0-15.2 mm, a width of 6.0-6.2 mm and a height of 3.9-4.7 mm.

Example 2a

A solid oral dosage form according to Example 2 is coated with a composition (see formulation below) according to the methodology of Example 1a.

Formulation

Cellulose H-P-M683	5.51 mg
Fe Oxide (Red) 17266	0.75
PEG 8000 (flakes)	1.0
Talc PH	3.99
Titanium dioxide PH	0.75
Deionised water	5.0
Ethanol + 5% Isopropyl alcohol	40.0

The tablets obtained have a length of 15.1-15.3 mm, a width of 6.1-6.3 mm and a height of 4.0-4.8 mm.

Example 3

Formula

valsartan	80.0 mg (40%)
AEROSIL 200	10.0 mg (5%)
L-HPC* L-11	87.0 mg (43%)
Magnesium Stearate	3.0 mg (1.5%)

AVICEL PH-301	10.0 mg (5%)
L-HPC* L-21	5.0 mg (2.5%)
AEROSIL 200	1.0 mg (0.5%)
Talc	2.0 mg (1.0%)
Magnesium Stearate	2.0 mg (1.0%)

* hydroxypropyl cellulose

200.0 mg

Method

The components (above the line) are blended in a container mixer. The blended material is sieved and pre-blended for an additional period of time in a container mixer. The blended material is compacted using a roller compactor (Bepex Pharmapaktor L 200/50 P, Hosokawa Micron Group) by applying a compaction force of 25-65 kN and a roller speed of 1.3-7.5 rpm. The compacted material is sieved again and the components below the line are added and final blended in a container mixer. Then 200 mg of the homogenous mixture is compressed into tablets using ovaloid punches (10 x 5.2 mm). The tablets obtained have a diameter of 8.5 mm and a thickness of 3.9 mm.

Example 3A

Film Coating

Titanium dioxide	1.00 mg
TC-5R*	3.68 mg
PEG 6000	0.66 mg
Talc	2.66 mg
	<hr/>
	8.00 mg

* = hydroxypropylmethyl cellulose.

Method

The film coating is applied to the solid oral dosage form of Example 3 according to the methodology of Example 1A.

The coated tablet has a diameter of 8.6 mm and a thickness of 4.0 mm.

[illegible]

Claims:

1. A solid oral dosage form comprising
 - a) an active agent containing an effective amount of valsartan or a pharmaceutically acceptable salt thereof and
 - b) pharmaceutically acceptable additives suitable for the preparation of solid oral dosage forms by compression methods

wherein the active agent is present in an amount of more than 35 % by weight based on the total weight of the solid oral dosage form.

2. A solid oral dosage form according to claim 1 wherein the active agent is present in an amount of more than 50 % by weight.
3. A solid oral dosage form according to claim 1 or claim 2 wherein the active agent is present in an amount ranging from 57 to 62 % by weight.
4. A solid oral dosage form according to any of the preceding claims wherein the active agent consists entirely of valsartan or a pharmaceutically acceptable salt thereof in a dosage of from between about 10 and 250 mg.
5. A solid oral dosage form according to any of the preceding claims wherein the dosage range is from 40 to 160 mg.
6. A solid oral dosage form according to any of the preceding claims wherein the dosage is 40 mg, 80 mg or 160 mg.

09203805.050799
66/050.50820260

7. A solid oral dosage form according to any of the claims 1 to 3 wherein the active agent consists of an effective amount of valsartan or a pharmaceutically acceptable salt thereof and an effective amount of hydrochlorothiazide (HCTZ).
8. A solid oral dosage form which comprises as therapeutic agents an effective amount of valsartan or a pharmaceutically acceptable salt thereof; an effective amount of HCTZ; and, pharmaceutically acceptable additives suitable for the preparation of solid oral dosage forms by compression methods.
9. A solid oral dosage form according to claims 7 or 8 comprising a unit dose of about 10 to 250 mg of valsartan or a pharmaceutically acceptable salt thereof and a unit dose of about 6 to 60 mg of HCTZ.
10. A solid oral dosage form according to any of the claims 7 to 9 comprising a unit dose of about 50 to 100 mg of valsartan or a pharmaceutically acceptable salt thereof and a unit dose of about 10 to 30 mg of HCTZ.
11. A solid oral dosage form according to any of the claims 7 to 9 comprising a unit dose of about 80 to 160 mg of valsartan or a pharmaceutically acceptable salt thereof and a unit dose of 12.5 mg or 25 mg of HCTZ.
12. A solid oral dosage form according to any of the preceding claims which comprises microcrystalline cellulose as a pharmaceutically acceptable additive.
13. A solid oral dosage form according to any of the preceding claims which comprises crosslinked polyvinylpyrrolidone (PVP) as a pharmaceutically acceptable additive.
14. A solid oral dosage form according to claim 12 wherein the microcrystalline cellulose is present in an amount of from 15 to 25 % by weight.

09202805.050799

15. A solid oral dosage form according to claim 13 wherein the crosslinked PVP is present in an amount of from 10 to 30 % by weight.
16. A solid oral dosage form according to any of the preceding claims in the form of a tablet.
17. A solid oral dosage form according to any of the preceding claims in the form of a dragée.
18. A process of forming a solid oral dosage form as defined in any of the preceding claims comprising the steps of
- i) grinding the active agent and pharmaceutically acceptable additives,
 - ii) subjecting a mixture of the ground active agent and additives to compression to form a coprimate
 - iii) converting the coprimate into granulate and
 - iv) compressing the granulate to form the solid oral dosage form.
19. A process according to claim 18 wherein the compression step ii) is carried out using roller compaction or slugging techniques.
20. A process according to claim 18 or 19 wherein step iii) is carried out by screening or milling the coprimate.
21. A process according to any of the claims 18 to 20 wherein the granulate is compressed without first being sized.

22. A process according to any of the claims 18 to 21 wherein the granulate is formed under a pressure of from 25 to 65 kN.
23. Coprimates obtained by roller compaction or slugging according to claim 19.
24. Granulate obtained according to the process according to claim 18.
25. A solid oral dosage form produced according to a method as defined in any of the claims 18 to 22.
26. A solid oral dosage form substantially as hereinabove defined with reference to any of the Examples.
27. Use of a solid oral dosage form as defined in any of the claims 1 to 17 in a method of treating hypertension (whether of the malignant, essential, reno-vascular, diabetic, isolated systolic, or other secondary type), congestive heart failure, angina (whether stable or unstable), myocardial infarction, arteriosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, left ventricular hypertrophy, cognitive dysfunction, e.g. Alzheimer's, stroke, headache and chronic heart failure.

DECLARATION AND POWER OF ATTORNEY FOR UNITED STATES PATENT APPLICATION

☒ Original ☐ Supplemental ☐ Substitute

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name, and

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if more than one name is listed below) of the subject matter which is claimed and for which a United States patent is sought on the invention entitled

SOLID ORAL DOSAGE FORMS OF VALSARTAN

the specification of which:

☐ is attached hereto.

☐ was filed on _____ as Application No. _____
(day/month/year)

and, if this box (☐) contains an *

☐ was amended on _____
(day/month/year)

☒ was filed as Patent Cooperation Treaty international Application No.

PCT/EP 97/03172 on 18/06/1997
(day/month/year)

and, if this box (☐) contains an *

☐ entered the national stage in the United States and was accorded Application No. _____

and, if this box (☐) contains an *

☐ was amended, subsequent to entry into the national stage, on _____
(day/month/year)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment(s) referred to above and, if this application was filed as a Patent Cooperation Treaty international application, by any amendments made during the international stage (including any made under Patent Cooperation Treaty Rule 91, Article 19 and Article 34).

I acknowledge my duty to disclose all information which is known by me to be material to the patentability of this application as defined in 37 C.F.R. § 1.56.

I hereby claim the benefit under 35 U.S.C. §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate listed below and under 35 U.S.C. §365(a) of any Patent Cooperation Treaty international application(s) designating at least one country other than the United States listed below and have also listed below any foreign application(s) for patent or inventor's certificate and Patent Cooperation Treaty international application(s) designating at least one country other than the United States for the same subject matter and having a filing date before that of the application the priority of which is claimed for that subject matter:

COUNTRY/REGION (OR P.C.T.)	APPLICATION No.	FILING DATE (day/month/year)	PRIORITY CLAIMED	
Great Britain	9613470.5	27/06/1996	<input checked="" type="checkbox"/> Yes	<input type="checkbox"/> No
			<input type="checkbox"/> Yes	<input type="checkbox"/> No
			<input type="checkbox"/> Yes	<input type="checkbox"/> No
			<input type="checkbox"/> Yes	<input type="checkbox"/> No
			<input type="checkbox"/> Yes	<input type="checkbox"/> No

I hereby claim the benefit under 35 U.S.C. § 119 (e) of any United States provisional application(s) listed below:

APPLICATION NO.	FILING DATE (day/month/year)
-----------------	---------------------------------

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s) listed below and under 35 U.S.C. §365(c) of any Patent Cooperation Treaty international application(s) designating the United States listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in said prior application(s) in the manner required by the first paragraph of 35 U.S.C. §112, I acknowledge my duty to disclose all information known to me to be material to patentability as defined in 37 C.F.R. §1.56 which became available between the filing date(s) of the prior application(s) and the national or Patent Cooperation Treaty international filing date of this application:

United States Application No.	United States Filing Date (day/month/year)	Status (Pending, Abandoned or U.S. Patent No.)	International Application No. and Filing Date
----------------------------------	--	--	--

I hereby appoint the registered practitioners associated with Customer No. 001095, respectively and individually, as my attorneys and agents, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

If these brackets contain an X [X], I hereby authorize the registered practitioners associated with Customer No. 001095 and any others acting on my behalf to take any action relating to this application based on communications from the Patents and Trademarks Division of Novartis Services AG, Basle, Switzerland, or an affiliate thereof or a successor thereto, without direct communication from me.

Please address all communications to Michael W. Glynn, Novartis Corporation, Patent and Trademark Department, 564 Morris Avenue, Summit, NJ 07901-1027.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full name of sole
or first joint inventor

1-00
Robert Frank WAGNER

Inventor's signature

Robert Frank Wagner

Date

27/1/99
(day/month/year)

Residence

Neshanic Station, USA *NJ*

Citizenship

USA

Post Office Address

1 Cedarview Court
Neshanic Station, NJ 08853
USA

IMPORTANT: Before this declaration is signed, the patent application (the specification, the claims and this declaration) must be read and understood by each person signing it, and no changes may be made in the application after this declaration has been signed.

09203805.1050799 662050 50820260

2-00

Full name of second joint inventor, if any

Yoshimitsu KATAKUSE

Inventor's signature

Y. Katakuse

Date

99.03.19
(day/month/year)

Residence

Hirakata, Japan JPK

Citizenship

Japan

Post Office Address

1-9-20, Hoshigaoka
Hirakata 573-0013
Japan

Full name of third joint inventor, if any

Takashi TAIKE

3-00

Inventor's signature

Takashi TAIKE

Date

99.01.26
(day/month/year)

Residence

Kobe, Japan JPK

Citizenship

Japan

Post Office Address

2-7-3, Shoubugaoka
Kitaku, Kobe 651-13
Japan

Full name of fourth joint inventor, if any

Fujiki YAMATO

4-00

Inventor's signature

Date

(day/month/year)

Residence

Takarazuka, Japan JPK

Citizenship

Japan

Post Office Address

3-5-504, Komyo-cho
Takarazuka 665-0045
Japan

Full name of second
joint inventor, if any

Yoshimitsu KATAKUSE

Inventor's signature

Date

(day/month/year)

Residence

Hirakata, Japan

Citizenship

Japan

Post Office Address

**1-9-20, Hoshigaoka
Hirakata 573-0013
Japan**

Full name of third
joint inventor, if any

Takashi TAIKE

Inventor's signature

Date

(day/month/year)

Residence

Kobe, Japan

Citizenship

Japan

Post Office Address

**2-7-3, Shoubugaoka
Kitaku, Kobe 651-13
Japan**

Full name of fourth
joint inventor, if any

Fujiki YAMATO

Inventor's signature

Fujiki Yamato

Date

29 March 1999
(day/month/year)

Residence

Takarazuka, Japan

Citizenship

Japan

Post Office Address

**3-5-504, Komyo-cho
Takarazuka 665-0045
Japan**

Full name of fifth
joint inventor, if any

5-00
Manfred KOHLMAYER

Inventor's signature

Manfred Kohlmeier

Date

18.01.99
(day/month/year)

Residence

Basel, Switzerland

CHX

Citizenship

Germany

Post Office Address

Thiersteinerallee 13
4053 Basel
Switzerland

09203805 050799
664050 50820260